drug safety

Latest Headlines

Latest Headlines

Congressional bills would toughen safety labeling for generic drugmakers

Congressional Democrats are ramping up two bills intended to put generic drugmakers on par with their Big Pharma counterparts as far as governing how they change product labeling to report updated safety information.

Health Canada tells hospitals to quarantine morphine from Sandoz

Sandoz Canada is in the spotlight again this week after Canadian health officials told hospitals to quarantine boxes of the company's injectable morphine after one was found to contain another drug.

Gilenya market share drops after FDA review

An FDA safety review is taking its toll on Gilenya sales. The Novartis ($NVS) multiple sclerosis pill, the first oral therapy for the debilitating disease, lost market share in January after reports that some patients died while using the drug.

Novartis to revamp Rasilez label with safety risks

The data on Rasilez 's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...

Jury says J&J's Risperdal didn't cause plaintiff's diabetes

A New Jersey jury has let Johnson & Johnson's ($JNJ) Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's...

Pakistan Supreme Court interjects itself in drug death scandal

The Supreme Court in Pakistan has now stepped into the controversy over allegedly contaminated drugs that have killed more than 130 people and sickened hundreds more. On Monday, the court directed...

Mediator probe rolls on with searches at Afssaps, executives' homes

The Mediator scandal in France continues as investigators searched the offices of healthcare regulators Afssaps and the homes of several of its executives. The agency faced a public outcry over its

FDA talks, but doctors don't necessarily listen

Poor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are

GSK resolves 20K more Avandia lawsuits, lawyer says

GlaxoSmithKline ($GSK) has reached a deal to settle another 20,000 lawsuits over its diabetes drug Avandia, a lawyer for the plaintiffs told Bloomberg. The settlement came out of court-ordered

New death reports prompt EMA review of Gilenya

European regulators are taking a closer look at Novartis' ($NVS) multiple sclerosis pill Gilenya. After the November death of a 59-year-old patient who'd just begun Gilenya therapy, triggering an FDA